Join AVITA Medical’s Upcoming Investor Webinar Event
AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL) is excited to invite its valued shareholders and interested investors to an informative investor webinar. The event will be hosted by Jim Corbett, the Chief Executive Officer, and David O’Toole, the Chief Financial Officer. It is slated for August 14, 2025, at 9 AM Australian Eastern Daylight Time. If you’re in the U.S., that translates to August 13 at 4 PM Pacific Standard Time.
What to Expect from the Webinar
The webinar promises to be an engaging session where attendees can learn about the company’s recent financial and operational milestones, notably from the second quarter of 2025. This session will conclude with a Q&A segment, allowing participants to pose their questions through the registration page, ensuring that the discussion is both informative and interactive.
How to Register
To attend the webinar, participants are encouraged to register in advance. Registration can be easily completed online and details are available on the AVITA Medical website. Following the presentation, a recorded playback will also be made accessible on the company’s website for those who are unable to attend live.
About AVITA Medical, Inc.
AVITA Medical is at the forefront of wound care technology, specializing in advanced therapeutic solutions designed to enhance the healing process. Their primary innovation, the RECELL System, is engineered to improve patient recovery times effectively. It has received FDA approval for treating thermal burns and trauma wounds. What sets the RECELL System apart is its ability to utilize a patient’s own skin to create Spray-On Skin™ Cells, which can lead to superior clinical outcomes directly at the point-of-care.
Innovative Products and Global Reach
In addition to the groundbreaking RECELL System, AVITA Medical holds exclusive rights to produce and distribute PermeaDerm®, a biosynthetic wound matrix, within the U.S. markets. The company also markets Cohealyx™, a unique collagen-based dermal matrix that expands their innovative offerings. Globally, the RECELL System has received multiple approvals allowing it to be used for a variety of skin healing applications. Notable approvals include TGA registration in Australia, CE mark authorization in Europe, and PMDA endorsement in Japan, showcasing the company’s broad international footprint.
Future Initiatives and Commitment to Healing
AVITA Medical is committed to continuous innovation in clinical care, striving to create technologies that streamline wound healing processes. Recent advancements and clinical data emphasize the effectiveness of their products, encouraging further investment and interest from the healthcare community.
Investor and Media Inquiries
For those seeking further information or who wish to engage with the company directly, inquiries can be directed to Ben Atkins at AVITA Medical. He is available via phone or email. This is an excellent opportunity for potential investors and media representatives to voice their questions and receive real-time updates about the company's activities and growth trajectory.
Frequently Asked Questions
1. What is the focus of the upcoming webinar?
The webinar will focus on AVITA Medical's second-quarter financial results and include a Q&A session for investors.
2. How can I participate in the webinar?
Interested individuals can register for the webinar on the AVITA Medical website, where they can also submit questions in advance.
3. What products does AVITA Medical specialize in?
AVITA Medical specializes in innovative wound care solutions, notably the RECELL System, which utilizes a patient’s own skin for wound healing.
4. How does the RECELL System benefit patients?
By using the RECELL System, patients may experience faster recovery times due to the technology’s ability to create Spray-On Skin™ Cells from their own skin.
5. Who can I contact for more information about AVITA Medical?
For inquiries regarding investing or media, you can reach out to Ben Atkins at AVITA Medical through the company’s provided email addresses.
